Design and rationale of MYOFLAME-19 randomised controlled trial: MYOcardial protection to reduce post-COVID inFLAMmatory heart disease using cardiovascular magnetic resonance Endpoints.
Puntmann VO, Beitzke D, Kammerlander A, Voges I, Gabbert DD, Doerr M, Chamling B, Bozkurt B, Kaski JC, Spatz E, Herrmann E, Rohde G, DeLeuw P, Taylor L, Windemuth-Kieselbach C, Harz C, Santiuste M, Schoeckel L, Hirayama J, Taylor PC, Berry C, Nagel E.
Puntmann VO, et al. Among authors: hirayama j.
J Cardiovasc Magn Reson. 2024 Oct 29;27(1):101121. doi: 10.1016/j.jocmr.2024.101121. Online ahead of print.
J Cardiovasc Magn Reson. 2024.
PMID: 39481808
Free PMC article.